Home | Pharmaceutical Outsourcing - The Journal of Pharmaceutical & Biopharmaceutical Contract Services

Close Ad ☒

Show Ad

Engaging with Regulators for Single-Arm Oncology Research Trials
When well-planned and well-executed, single-arm trials can accelerate access to life-saving therapies that might otherwise never reach desperate cancer patients. read more
How Early Data Drives Better Cell Line Performance
In the race to bring new biologics to market, development teams are constantly balancing speed, quality, and regulatory expectations. Yet one factor often determines long-term success more than any other: the strength of the data generated in the earliest phases of cell line development. read more
Status Of AI Regulation On Drug Development
As AI capabilities scale, the FDA expects sponsors and their outsourcing partners to treat AI like any other regulated, computerized system that can influence safety, effectiveness, or quality–define the role, document credibility, control the lifecycle, and monitor performance. read more
Safely Scaling Highly Potent API manufacturing
Ever more drug developers are searching for CDMOs with contamination-limiting capabilities. But how can they know which have these high-potency credentials? read more

Clinical Trials - Transforming Drug Development
Transforming Drug Development: Accelerating Clinical Trials through Patient-Centric Innovations and Technological Breakthroughs Watch Now

Cellipont Bioservices Announces Release of 100th GMP Batch
Thursday, July 30, 2026
Cellipont Bioservices announced the successful release of its 100th GMP batch at its manufacturing facility in The Woodlands, Texas. read more
Piramal Pharma Starts FY27 With 17% Revenue Growth, Higher EBITDA
Thursday, July 30, 2026
Piramal Pharma said it began FY27 with stronger revenue and margin expansion, driven by broad-based growth across its contract development and ... read more
Harbour BioMed, Sinopharm Form R&D Consortium for Innovative Biologics
Wednesday, July 29, 2026
Harbour BioMed and China National Pharmaceutical Group announced a strategic collaboration to establish a joint innovation R&D consortium focused on ... read more
AsymBio Breaks Ground on Fengxian R&D Building to Expand Biologics Services
Wednesday, July 29, 2026
AsymBio has begun construction of a new R&D building at its Shanghai Fengxian site, a move the company said will strengthen its biologics CDMO ... read more
ICON, Anthropic Launch Multi-Year AI Collaboration for Clinical Trials
Tuesday, July 28, 2026
ICON has announced a multi-year collaboration with Anthropic to bring Claude’s AI capabilities across the clinical trial lifecycle, expanding the ... read more